AJMC - Managed Care News, Research, and Expert Insights
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
AJMC - Managed Care News, Research, and Expert Insights
About the Journal. An independent, peer-reviewed, monthly publication dedicated to disseminating clinical information to managed care physicians, clinical decision makers, and …
Issues Of The American Journal of Managed Care - AJMC
The American Journal of Managed Care® is the leading peer-reviewed journal dedicated to issues in managed care. Founded in 1995, it is an independent, peer-reviewed, monthly …
The American Journal of Managed Care - AJMC
About AJMC. Purpose: Founded in 1995, The American Journal of Managed Care ® (AJMC ®) provides a forum for peer-reviewed literature on healthcare outcomes research.It is an …
Clinical - AJMC
2025年1月13日 · The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of …
About Us - AJMC
The American Journal of Managed Care® (AJMC®) is a leader in managed care research, offering actionable insights and peer perspectives through our leading peer-reviewed journals, …
American Journal of Managed Care News & Expert Insights - AJMC
The American Journal of Managed Care News section is a comprehensive resource for clinical news and expert insights. Read more at AJMC.
Latest Conference Articles - AJMC
2025年1月15日 · The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and …
Year in Review: Non-Small Cell Lung Cancer - ajmc.com
23 小时之前 · This year in review of 2024 milestones in non–small cell lung cancer (NSCLC) features coverage of the LAURA trial presented in June at the American Society of Clinical …
Abelacimab, a “Game Changer” for High-Risk Patients With AFib: …
2 天之前 · Key Takeaways. Abelacimab shows a 62% reduction in major or clinically relevant non-major bleeding compared to rivaroxaban in AFib patients. The study highlights an 89% …